← All trials
NCT05085275
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 30, 2021
- Primary completion
- Mar 31, 2024
- Completion date
- Jun 30, 2024
- First posted
- Oct 20, 2021
- Last posted
- Oct 20, 2021
- Enrollment
- 1000
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- USRC Kidney ResearchLead sponsor
- Akebia TherapeuticsCollaborator
- USRC Kidney ResearchOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.